Adicet Bio (ACET) Total Non-Current Liabilities (2017 - 2026)

Adicet Bio's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $29.3 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 1.32% year-over-year to $29.3 million; the TTM figure through Mar 2026 stood at $29.3 million (down 1.32% YoY), while the FY2025 annual figure was $33.1 million, down 1.23% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $29.3 million, down from $33.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $38.6 million in Q1 2023, with the low at $29.3 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $34.2 million (2024), against an average of $34.2 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities sank 35.3% in 2022, then jumped 32.1% in 2023.
• Adicet Bio's Total Non-Current Liabilities stood at $38.2 million in 2022, then retreated by 3.26% to $37.0 million in 2023, then slipped by 9.45% to $33.5 million in 2024, then decreased by 1.23% to $33.1 million in 2025, then retreated by 11.38% to $29.3 million in 2026.
• Business Quant data shows ACET's Total Non-Current Liabilities at $29.3 million in Q1 2026, $33.1 million in Q4 2025, and $31.2 million in Q3 2025.